---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-011888"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:04:35.368020+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences cancels $65M+ debt via stock issuance to executive chairman at $6.51/share

## Summary
- Issues 10,022,937 shares to Robert W. Duggan at $6.51 (1%+ premium to $6.44 close) in private placement.
- Cancels $65M principal plus ~$0.25M accrued interest; loan agreement terminates without fees.
- Duggan's beneficial ownership increases from ~62% to ~69% post-closing; no warrants or placement fees.
- Transaction expected to close on or about May 8, 2023, subject to customary conditions.
- CEO says debt elimination strengthens balance sheet for developing nsPFA cardiac devices.

## SEC filing metadata
- accession: 0001437749-23-011888
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774923011888/0001437749-23-011888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774923011888/plse20230430_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-011888
- JSON: https://secwatch.observer/filing/0001437749-23-011888.json
- Plain text: https://secwatch.observer/filing/0001437749-23-011888.txt

## Key facts
- Material Agreements
  PULSE BIOSCIENCES, INC. terminated Loan Agreement with Robert W. Duggan valued at Cancellation of $65 million aggregate principal amount plus accrued interest; Loan Agreement termina (effective 2023-04-30).
  - Action: termination
  - Agreement: credit facility
  - Counterparty: Robert W. Duggan
  - Value: Cancellation of $65 million aggregate principal amount plus accrued interest; Loan Agreement termina
  - Effective: 2023-04-30
  source text: Item 1.02 Termination of a Material Definitive Agreement. The description of the termination of the Loan Agreement set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.02 in its entirety.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774923011888/0001437749-23-011888-index.htm
- Material Agreements
  PULSE BIOSCIENCES, INC. entered into Securities Purchase Agreement with Robert W. Duggan valued at 10,022,937 shares of common stock at $6.51 per share (effective 2023-04-30).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Robert W. Duggan
  - Value: 10,022,937 shares of common stock at $6.51 per share
  - Effective: 2023-04-30
  source text: On Sunday, April 30, 2023, Pulse Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Robert W. Duggan (“Investor”), the Company’s Executive Chairman of the Board of Directors and majority stockholder of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774923011888/0001437749-23-011888-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.